Testing MT-125 for newly diagnosed glioblastoma
Part of Cancer clinical trials.
This trial tests a new drug called MT-125 for people with a specific type of brain cancer called glioblastoma (GBM) that is IDH wildtype and MGMT unmethylated. The study will see if MT-125 is safe and tolerable, and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have newly diagnosed GBM that is IDH wildtype and MGMT unmethylated.
- You must be able to care for yourself (ECOG score 0, 1, or 2).
- You must have adequate organ function (kidney, liver, blood counts, heart).
- You must be on a stable dose of steroids for at least 2 weeks before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests an experimental drug (BGB-58067) for people with a newly diagnosed glioblastoma that has a specific gene deletion (MTAP). It aims to see if the drug can shrink the tumor or slow its growth.
This trial tests whether customized drug screening on your tumor cells can help doctors choose the best treatment for you. Your tumor cells will be grown in the lab and tested against different drugs to find what works best, combined with short-course radiation therapy.
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
This study tests whether a new drug called MT-125, combined with standard radiation and chemotherapy, is safe and effective for patients with a specific type of brain tumor (glioblastoma) that has a particular genetic feature (MGMT methylation). The goal is to see if this combination helps patients live longer without serious side effects.
This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.
This Phase 1/2 trial tests two experimental treatments delivered through a thin catheter placed in the brain for people with newly diagnosed glioblastoma (GBM). The goal is to see whether the treatment can be given safely and whether it may shrink or control the tumor after standard chemotherapy and radiation.
Hear when a new Glioblastoma (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.